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Abstract
Background: This paper investigates the effects of a new radiosensitizer, doranidazole, and
enhancing irradiation on colorectal cancer cells.
Methods: The radiosensitizing effect of doranidazole was determined using colony formation and
propidium iodide (PI) assays to measure cell growth inhibition and the cell killing effect of human
colorectal cancer cell lines exposed to high doses of γ-ray irradiation under hypoxic conditions in
vitro. Fluorescence staining and cell migration assays were also used to assess the radiosensitizing
effect.
Results: Cell proliferation evaluated by clonogenic survival curves was significantly inhibited by 5
mmol/L doranidazole, particularly at doses ranging from 10 to 30 Gy of irradiation. The
radiosensitizing effect of doranidazole on colorectal cancer cells occurs in a time- and dose-
dependent manner. Doranidazole also inhibited the mobility of cell invasion and migration.
Conclusion:  Doranidazole can enhance the killing effect and the cell growth inhibition of
colorectal cancer after high-dose irradiation in a time and dose-dependent manner.
Background
Colorectal cancer is the fourth most common malignant
tumor worldwide [1]. Local recurrence is a challenge in
the treatment of colorectal cancer, since it disables the
transference and it is difficult to treat [2]. The incidence of
local recurrence ranges from 15 to 45 percent after con-
ventional surgery, in which blunt dissection of the color-
ectal fascia often fails to remove all of the tissue that may
bear a tumor [3]. In an attempt to improve local control
and survival after conventional surgery, radiotherapy is
one of the major adjuvant therapies for colorectal cancer.
Preoperative radiotherapy and postoperative radiotherapy
might reduce the risk of local recurrence and improve sur-
vival rates [4]. A recent meta-analysis concluded that the
combination of preoperative radiotherapy and surgery, as
compared with surgery alone, significantly improved
overall survival and cancer-specific survival [5,6]. How-
ever, the radiation response is limited because of the pres-
ence of radio-resistant hypoxic cells within solid tumors
[7].
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Several members of the family of hypoxic radiosensitizers
have been extensively explored over the past 30 years [8],
and nitroimidazole derivatives are major compounds
examined in clinical studies [9]. However, most clinical
trials have failed to document a significant sensitizing
effect [10,11]. In these clinical studies, low doses of drugs
were used repeatedly with fractionated irradiation
because of their side effects, such as neurotoxicity.
Doranidazole, a 2-nitroimidazole-nucleoside derivative,
was synthesized to reduce the lipophilicity of nitroimida-
zole derivatives and to prevent the accumulation of the
drug in the central and peripheral nervous systems [12].
Doranidazole can be given at high doses during intraop-
erative high-dose irradiation. It has been shown that dora-
nidazole suppresses the re-growth of a subcutaneously
implanted mouse tumor after 20 Gy irradiation [13].
In our previous study, we reported the radiosensitizing
effect of doranidazole on human pancreatic cancer cells
after high-dose irradiation under hypoxic conditions [14].
In the present study, we examined the radiosensitizing
effect of doranidazole on human colorectal cancer cells by
high-dose irradiation in vitro.
Methods
Cells and cell culturing conditions
The five human colorectal cell lines used in this study: HT-
29, DLD-1, Colo 201, LoVo, and SW620, were obtained
from the Japanese Cancer Research Resources Bank
(Tokyo, Japan). Cells were maintained in Dulbecco's
Modified Eagle's Medium (DMEM, Sigma Chemical Co.,
St. Louis, MO) supplemented with 10% fetal bovine
serum (FBS), streptomycin (100 mg/mL), and penicillin
(100 u/mL) at 37°C in a humidified atmosphere contain-
ing 95% air and 5% CO2. The experiments were per-
formed 24 h after plating cells in Falcon flat-bottom 24-
well plates (Becton-Dickinson, Lincoln Park, NJ) during
logarithmic growth. All of the procedures were performed
in triplicate, and each was repeated at least three times.
Chemicals
Doranidazole, provided by POLA Chemical Industry Inc.
(Yokohama, Japan), was dissolved in phosphate-buffered
saline (PBS). Cells were treated with doranidazole for 1 h
during irradiation at various concentrations (indicated
below). After irradiation, the cells were washed with PBS
and fresh medium was added. Anticancer agents, VP-16,
5-FU, SN-38, and cisplatin were provided by Sigma
Chemical Co.. The anticancer agents were applied to cells
continuously during the entire experimental period.
Irradiation
Cells in 24-well plates were irradiated with three different
doses (10, 20 and 30 Gy) at room temperature with a
137Cs source (Gamma Cell 40, Atomic Energy of Canada
Ltd., Mississauga, Canada) delivering 1.0 Gy/min. During
irradiation, hypoxia was maintained in cells by placing
plates in a closed chamber and flushing with 100% N2 30
min prior to the treatment, as described previously [14].
Cell death detection
We assessed the radiosensitizing effect of doranidazole on
the colorectal cancer cells by determining the extent of cell
death by the fluorescence intensity of PI stained cells, as
described previously [5]. Briefly, PI was added to each well
to a final concentration of 30 mmol/L, and the initial flu-
orescence intensity from the dead cells was measured in a
multi-well plate reader, VICTOR 3 1420 Multi-label
Counter (Perkin Elmer, Wallac Oy Inc., Turku, Finland)
with 530-nm excitation and 645-nm emission filters.
Digitonin (600 nM) was added to each well to permeabi-
lize all cells and label all nuclei with PI following the ini-
tial assessment of intensity. After a 30 min incubation, the
fluorescence intensity was measured again to obtain a
value corresponding to the total number of cells. The per-
centage of dead cells was calculated as the proportion of
the initial fluorescence intensity over that corresponding
to the total number of cells.
Colony forming assay and cell survival curve
The number of colonies was determined as described pre-
viously [16]. Briefly, after treatment with irradiation and
doranidazole, cells were trypsinized, counted, and seeded
for the colony forming assay in 60 mm dishes at 300 cells
per dish. After incubation for 14 days, colonies were
stained with crystal violet and the number of positive cells
was counted. Colonies containing more than 50 cells were
scored, and triplicates containing 10–150 colonies/dish
were counted in each treatment.
In both of the experiments performed under hypoxic con-
dition, the cell surviving fraction was determined by a
standard in vitro colony formation assay and cell survival
curve. The sensitizer enhancement ratio (SER) was calcu-
lated from two radiation doses with or without doranida-
zole to reduce cell survival to 1%.
SER = irradiation D0/(irradiation + doranidazole) D0
Morphological observation with fluorescence microscopy
The extent of cell killing via apoptosis was assessed by flu-
orescence microscopy, using the nuclear fluorophore
Hoechst 33258 (Ho258) and a Leica inverted microscope
(DM IRB, Leica, Germany). The cells were cultured in 24-
well plates and observed 4 days after treatment with irra-
diation and/or doranidazole. Thirty minutes before view-
ing, the cells were treated with 5 mmol/L Ho258. Images
were acquired using a Spot-2 cooled CCD digital cameraBMC Cancer 2007, 7:188 http://www.biomedcentral.com/1471-2407/7/188
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(DC300F, Leica) and 365–395 nm excitation, with an
emission range of 435–485 nm.
Cell migration and invasion assays
Cell matrigel invasion and migration assays were per-
formed as previously described [17]. A total of 5 × 104
cells in 500 µL of serum-free DMEM were added to the
upper chamber of Boyden chambers (Transwell, 6.5 mm
diameter, 8 µm pore filter; Costar, Cambridge, MA) and
allowed to migrate for 24 h at 37°C under cell culture
conditions. DMEM (500 mL) containing 10% FBS was
added to the bottom chamber and used as a chemo
attractant. Cells were removed from the upper chamber
with a cotton swab and the cells that migrated to the lower
surface of the membrane were fixed, stained with hema-
toxylin and eosin (H&E) and counted.
Statistical analysis
For the cell survival assay, experimental procedures were
performed in triplicate, and the results were expressed as
the mean ± SD from three or four independent experi-
ments. Statistical significance was analyzed with the
Mann-Whitney t-test using Statview software (JMP, Cary,
NC, USA) P < 0.05 was considered to be statistically sig-
nificant.
Results
The effect of doranidazole on cell viability and killing in a 
human colorectal cancer cell line, Colo 201
To determine the cytotoxicity of doranidazole on human
colorectal cancer cells, we examined Colo 201 cells by PI
assay (as described in the Materials and Methods). As
shown in Figure 1, doranidazole alone did not cause any
cell growth or a cell killing enhancement effect at 5 mmol/
L under either aerobic or hypoxic conditions (data not
show).
Doranidazole radiosensitizes the cell growth viability of 
Colo 201 cells under hypoxic conditions
Treated with and without doranidazole during irradia-
tion, Colo 201 cells were irradiated under hypoxic condi-
tions for 1 h at doses of 2, 4, 8, 12, 16, 20 and 30 Gy. The
cell growth ratio was determined by colony assay 2 weeks
after treatment. As shown in Figure 2, cell proliferation
was affected by irradiation alone in a dose-dependent
manner; in contrast, the addition of 5 mmol/L doranida-
zole significantly reduced the cell survival rate under
hypoxic conditions. The SER of doranidazole was deter-
mined for Colo 201 cells after irradiation under hypoxic
conditions. The SER of doranidazole for low dose irradia-
tion (2 – 10 Gy) was 1.26, and that for high dose irradia-
tion (10–30 Gy) was 1.79.
The enhancement effect of doranidazole on cell killing 
under hypoxic conditions after high-dose irradiation in 
colorectal cancer cell lines
The effect of doranidazole was examined in different cell
samples following treatment with different doses of irra-
diation. As shown in Figure 3, 4 days after the irradiation,
the percentage of dead cells was augmented and corre-
lated with increasing doses of irradiation: 18.5% with 10
Gy, 27.8% with 20 Gy, and 57.9% with 30 Gy. The addi-
tion of 5 mmol/L doranidazole significantly increased the
cell death by approximately 85%, 70%, and 30%, respec-
tively. Similarly, with the addition of 5 mmol/L doranida-
zole, the cell killing by 30 Gy irradiation under hypoxic
conditions was significantly increased from 22.2% to
36.4% in five colorectal cancer cell lines (Table 1).
Cell survival curve of Colo 201 after different doses of irradi- ation under hypoxia in the presence or absence of 5 mmol/L  Doranidazole Figure 2
Cell survival curve of Colo 201 after different doses of irradi-
ation under hypoxia in the presence or absence of 5 mmol/L 
Doranidazole.
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Time-course experiments confirmed the enhancing effect 
of doranidazole in Colo 201 cells
As shown in Figure 4, significant cell killing was found 3
days after 30 Gy irradiation, and the percentage of cell kill-
ing was significantly increased in the presence of 5 mmol/
L doranidazole 2 days following the irradiation.
A dose-dependent analysis of doranidazole revealed that
cell killing with 30 Gy irradiation increased with increas-
ing doses of doranidazole, and a statistically significant
increase in cell death was observed at doses greater than 5
mM (data not shown), as published previously for other
tumor cells (14).
Morphological changes of Colo 201 cells treated with 
doranidazole after 30 Gy irradiation under hypoxia
Four days after irradiation, the incubated Colo 201 cells
were stained with Ho258 and observed using a micro-
scope. As shown in Figure 5, the cells irradiated with 30
Gy irradiation showed damage including swelling, mem-
brane dissolution and formation of debris. Some cells
also showed nuclear fragmentation, which is a manifesta-
tion of apoptosis. These damage effects were aggravated as
the concentration of doranidazole increased from 5 to 10
mmol/L.
Analysis of the cell migration assay of Colo 201 cells after 
irradiation
The number of cells that migrated to the lower surface of
the membrane 24 h after 30 Gy irradiation was signifi-
cantly lower than that of the control cells. Furthermore,
the number of cells that had migrated was significantly
reduced by doranidazole in a dose-dependent manner
(Figure 6).
The radiosensitizing effects of four anticancer agents on 
Colo 201 cells compared to those of doranidazole
Using 30 Gy irradiation with VP-16, cisplatin, SN-38, 5-
FU or doranidazole, we increased the rate of cell killing
significantly compared to that with irradiation alone.
Treatment with the anticancer agents alone at the radio-
sensitizing doses significantly killed Colo 201 cells, which
Serial measurement of cell death of human colorectal cancer  cell line, Colo 201, after 30 Gy irradiation under hypoxia in  the presence or absence of 5 mmol/L doranidazol Figure 4
Serial measurement of cell death of human colorectal cancer 
cell line, Colo 201, after 30 Gy irradiation under hypoxia in 
the presence or absence of 5 mmol/L doranidazol.
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Table 1: The effect of doranidazole on human colorectal cell lines 3 days after irradiation under hypoxia
Irradiation Dead Cells (%)
VoLo HT-29 DLD-1 Colo 201 SW 620
30 Gy irradiation 15.7 ± 1.6 21.9 ± 3.7 16.7 ± 1.9 12.7 ± 2.4 19.5 ± 0.9
30 Gy irradiation + 
Doranidazole (5 mM)
22.2 ± 2.9 * 33.8 ± 4.0 * 28.9 ± 3.5 * 31.4 ± 1.9 * 27.0 ± 1.9 *
* P < 0.01, compared with 30 Gy irradiation
Killing of a human colorectal cancer cell line, Colo 201,  exposed to different doses of irradiation under hypoxia Figure 3
Killing of a human colorectal cancer cell line, Colo 201, 
exposed to different doses of irradiation under hypoxia.
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contrasted with the noncytotoxic effects of doranidazole
(Table 2).
Discussion
The results of the present study clearly demonstrate that
doranidazole enhances the growth inhibition and killing
of human colorectal cancer cells exposed to high-dose
irradiation under hypoxic conditions. The results were
confirmed by cell growth and cell killing assays, apoptotic
analysis, morphologic observations, and matrigel inva-
sion and migration assays. The cell killing doses of irradi-
ation adopted in the present study are comparable to
those used in clinical practice during intraoperative irradi-
The cell migration assay of human colorectal cancer cell line, Colo 201 after irradiation under hypoxia condition in the pres- ence or absence of doranidazole Figure 6
The cell migration assay of human colorectal cancer cell line, Colo 201 after irradiation under hypoxia condition in the pres-
ence or absence of doranidazole.
Control 30Gy Irradiation
30 Gy  Irradiation + 
Doranidazole 5 mmol/L 
30 Gy  Irradiation + 
Doranidazole 10 mmol/L
The nuclear morphologic changes of Colo 201 cells after  irradiation under hypoxia condition in the presence or  absence of Doranidazole Figure 5
The nuclear morphologic changes of Colo 201 cells after 
irradiation under hypoxia condition in the presence or 
absence of Doranidazole.
Control 30Gy Irradiation
30 Gy  Irradiation + 
Doranidazole 5 mmol/L 
30 Gy  Irradiation + 
Doranidazole 10 mmol/L
Table 2: Effect of doranidazole and anticancer agents on the cell 
killing of Colo 201 cell exposed to 30 Gy irradiation under 
hypoxia
Drugs Dead cells (%)
No-irradiation 30 Gy irradiation
Control 0.2 ± 0.3 18.4 ± 3.4
Doranidazole (5 µM) 0.8 ± 6.3 35.8 ± 4.4 *
VP-16 (5 µM) 24.4 ± 1.7 36.9 ± 1.2 *
Cisplatin (10 µM) 27.1 ± 0.3 38.1 ± 3.5 *
SN-38 (10 µM) 21.2 ± 6.7 37.4 ± 9.1 *
5-FU (50 µM) 31.5 ± 1.8 47.6 ± 2.7 *
* P < 0.01, compared with 30 Gy groupBMC Cancer 2007, 7:188 http://www.biomedcentral.com/1471-2407/7/188
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ation for the treatment of advanced colorectal cancer. The
doses of doranidazole used in the present experiment are
achievable in patients when administered intravenously,
and have been demonstrated previously in pancreatic can-
cer cells [14]. Taken together, doranidazole may function
as a potential sensitizer of intraoperative radiotherapy for
advanced colorectal cancer.
As a radiosensitizer, the clinical benefit of doranidazole is
different from that of anticancer agents. As shown in the
present study, anticancer agents not only enhance the cell
killing resulting from high dose irradiation, but they also
kill cells without irradiation. At radiosensitizing doses
anticancer agents have adverse effects on non-irradiated
organs, including the bone marrow and intestines. In con-
trast, treatment of cells with doranidazole alone did not
cause any cytotoxic effects to either normal fibroblasts or
malignant colorectal cancer cells. Meanwhile, systemically
administered doranidazole will cause the enhancing
effects only on the irradiated tumor and will not harm the
surrounding non-irradiated normal tissues.
The radiosensitizing effects of doranidazole on cell killing
and cell growth inhibition may facilitate the success of
pre-operative or post-operative irradiation in cases of
advanced colorectal cancer, particularly by enhancing the
inhibition of cancer cell metastasis of colorectal cancer
after irradiation. Therefore, doranidazole and intraopera-
tive irradiation will reduce the incidence of local recur-
rence after the conventional surgery for colorectal cancer.
In a previous study, we reported the radiosensitizing effect
of doranidazole on human pancreatic cancer cells [14]. In
the present study, we confirm the radiosensitizing effect of
doranidazole on human colorectal cancer cells. The
results clearly indicate that doranidazole may reduce the
risk of local recurrence and improve survival rates after the
combination of pre-operative or intraoperative radiother-
apy and surgery. Taken together, doranidazole will work
as a potential sensitizer of radiotherapy for human color-
ectal cancer.
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